Table 1.

Eligibility criteria for searches of RCTs in patients with IBD or uveitis treated with pharmaceutical drugs recognized as treatments for PsA.

Factor	Inclusion Criteria	Exclusion Criteria
Study design	RCTs of any design (individual or cluster randomization, step-wedge design). Secondary, post hoc, and subgroup analyses of individual RCTs. Extension studies of RCTs.	Secondary evidence (ie, systematic reviews, guidelines/ recommendations, evidence-based synopses). Quantitative primary studies that are not RCTs (eg, nonrandomized controlled studies, before-and-after studies, cohort studies, case studies, case series). Qualitative studies. Conference abstracts. Editorials, commentaries, trial protocols, letters, etc.
Participants and conditions of interest	Adult populations (age ≥ 18 yrs; if mixed ages, include if results for adults are reported separately or if most participants are adults). Diagnosis of IBD (UC, CD, subclinical colitis) or uveitis.	Pediatric only focus (< 18 yrs).
Interventions or exposures	Any DMARD, targeted synthetic or biologic drug or combination used in the treatment of PsA (oral, injection, IV).	Nonpharmacological interventions. NSAIDs only. Steroids only.
Comparisons or control groups	Any comparator (active, sham, PBO).	NA.
Outcomes of interest	Symptoms and signs including outcomes relating to disease activity and impact. Disease progression. Safety outcomes (AEs, side effects). Any length of follow-up will be considered.
Setting	Any.

AE: adverse event; CD: Crohn disease; DMARD: disease-modifying antirheumatic drug; IBD: inflammatory bowel disease; IV: intravenous; NA: not applicable; NSAID: nonsteroidal antiinflammatory drug; PBO: placebo; PsA: psoriatic arthritis; RCT: randomized controlled trial; UC: ulcerative colitis.